Beam Therapeutics Q3 net loss $96.7M; cash $925.8M; BEAM-101 enrollment at 35 patients

Beam Therapeutics Inc.

2024-Q3 EPS reported -$3.49 revenue$33,451,000

Net loss $96.7M ($1.17/share) vs $96.1M ($1.22) Q3 2023; R&D $94.3M, G&A $26.5M.
Cash, equivalents, and marketable securities $925.8M as of Sep 30, 2024; runway into 2027.
BEACON trial of BEAM-101: 35 patients enrolled, 8 dosed in sickle cell disease; ASH data Dec 2024.
First cohort dosing complete for BEAM-302 in alpha-1 antitrypsin deficiency; initial data expected 2025.
ESCAPE platform (BEAM-103/104) nominated for development in SCD and beta-thalassemia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.